We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The FDA has ordered GlaxoSmithKline (GSK) to halt a clinical trial of a drug candidate in the same class of drugs as Biogen Idec’s and Elan’s multiple sclerosis (MS) treatment Tysabri, which was recently withdrawn for safety reasons.